18.24
Schlusskurs vom Vortag:
$17.00
Offen:
$16.78
24-Stunden-Volumen:
3.28M
Relative Volume:
1.63
Marktkapitalisierung:
$1.70B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-10.08
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
+7.29%
1M Leistung:
-21.72%
6M Leistung:
-21.21%
1J Leistung:
-23.68%
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BEAM
Beam Therapeutics Inc
|
18.24 | 1.70B | 352.57M | -143.01M | -153.40M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2022-12-13 | Eingeleitet | Citigroup | Buy |
2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
2022-01-05 | Eingeleitet | Guggenheim | Buy |
2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
2021-09-24 | Fortgesetzt | Stifel | Buy |
2021-09-10 | Eingeleitet | BofA Securities | Buy |
2021-05-11 | Eingeleitet | Redburn | Buy |
2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-01-06 | Eingeleitet | Stifel | Hold |
2020-08-05 | Eingeleitet | William Blair | Outperform |
2020-03-02 | Eingeleitet | Barclays | Overweight |
2020-03-02 | Eingeleitet | JP Morgan | Overweight |
2020-03-02 | Eingeleitet | Jefferies | Buy |
2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st
How To Trade (BEAM) - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN
Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com
Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com
Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com
Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire
Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga
Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa
Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia
Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada
Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock - Investing.com
Beam Therapeutics president sells $136,418 in stock - Investing.com
Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
Beam Therapeutics Becomes Oversold - Nasdaq
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance
8 Best Gene-Editing Stocks to Buy - Insider Monkey
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on P - GuruFocus
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):